RecruitingNot Applicable

Immune Modulation by Exosomes in COVID-19

Germany40 participantsStarted 2021-12-22

Plain-language summary

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Critically ill COVID-19 patients with lung dysfunction * COVID-19 WHO severity degree \>= 4, ARDS (WHO Definition 13 March 2020) * Body weight \> 50 kg * Informed consent Exclusion Criteria: * Pregnant or breast feeding women

What they're measuring

Cytokine profile in supernatants

Timeframe: 24 hours, 1 year

Trial details

NCT IDNCT05191381

SponsorUniversity of Ulm

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-31

Contact for this trial

Manfred Weiss, MD

+49(0)731500 manfred.weiss@uniklinik-ulm.de

View on ClinicalTrials.gov More COVID-19 trials